Ethnicity and socio-economic status affects the incidence and survival of hepatosplenic T-cell lymphoma.
Mark J BishtonColin J CrooksTimothy R CardProf Joe WestPublished in: British journal of haematology (2024)
To address the lack of contemporary population-based epidemiological studies of hepatosplenic T-cell lymphoma (HSTCL), we undertook a population-based study of ICD-O-3-coded HSTCL in England. We used the National Cancer Registration Dataset and linked datasets on hospital admissions, Systemic Anti-Cancer Therapy, socio-demographics, comorbidities and death, identifying cases from 1 January 2013 to 31 December 2019 with survival data up to 5 January 2021. Crude and directly age-standardised incidence rates per million persons per year were calculated. Crude and adjusted incidence rate ratios compared incidence between groups using Poisson regression. A Cox proportional hazards model estimated mortality risks adjusted for age, sex, ethnicity, deprivation and allogenic stem cell transplant (allo-SCT; time varying). We identified 44 patients, mean age 42 years. Median survival was 11 months, and 1 and 5 year survivals were 48% (95% CI 29%-43%) and 22% (95% CI 12%-42%) respectively. The age-standardised incidence was 0.1 per million/year. Incidence was higher in areas with greater deprivation (0.15 per million/year), and more cases than expected were in non-White patients (39%). Non-Whites had a twofold increased risk of death (adjusted hazard ratio 2.21 [95% CI 1.03-4.78]) even after adjusting for deprivation, younger age and allo-SCT. In conclusion, ethnicity and socio-economic status affect both the incidence and survival of HSTCL.
Keyphrases
- risk factors
- end stage renal disease
- stem cells
- ejection fraction
- newly diagnosed
- cancer therapy
- peritoneal dialysis
- prognostic factors
- cardiovascular disease
- type diabetes
- mesenchymal stem cells
- patient reported outcomes
- risk assessment
- coronary artery disease
- cardiovascular events
- bone marrow
- big data
- human health